CN102439153B - 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 - Google Patents

用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 Download PDF

Info

Publication number
CN102439153B
CN102439153B CN201080022634.7A CN201080022634A CN102439153B CN 102439153 B CN102439153 B CN 102439153B CN 201080022634 A CN201080022634 A CN 201080022634A CN 102439153 B CN102439153 B CN 102439153B
Authority
CN
China
Prior art keywords
agonist
tlr9
tlr2
agonists
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080022634.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102439153A (zh
Inventor
伯顿·迪基
迈克尔·图维姆
斯科特·埃文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to CN201510337464.6A priority Critical patent/CN105126072B/zh
Priority to CN201310588997.2A priority patent/CN103800906B/zh
Publication of CN102439153A publication Critical patent/CN102439153A/zh
Application granted granted Critical
Publication of CN102439153B publication Critical patent/CN102439153B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201080022634.7A 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 Active CN102439153B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510337464.6A CN105126072B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
CN201310588997.2A CN103800906B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16313709P 2009-03-25 2009-03-25
US61/163,137 2009-03-25
US17924609P 2009-05-18 2009-05-18
US61/179,246 2009-05-18
PCT/US2010/028658 WO2010111485A1 (en) 2009-03-25 2010-03-25 Compositions for stimulation of mammalian innate immune resistance to pathogens

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510337464.6A Division CN105126072B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
CN201310588997.2A Division CN103800906B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物

Publications (2)

Publication Number Publication Date
CN102439153A CN102439153A (zh) 2012-05-02
CN102439153B true CN102439153B (zh) 2015-07-22

Family

ID=42237276

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201080022634.7A Active CN102439153B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
CN201510337464.6A Active CN105126072B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
CN201310588997.2A Active CN103800906B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510337464.6A Active CN105126072B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
CN201310588997.2A Active CN103800906B (zh) 2009-03-25 2010-03-25 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物

Country Status (15)

Country Link
US (6) US8883174B2 (enExample)
EP (1) EP2411521B1 (enExample)
JP (2) JP5759445B2 (enExample)
KR (2) KR101856462B1 (enExample)
CN (3) CN102439153B (enExample)
AU (1) AU2010229835B2 (enExample)
BR (1) BRPI1009842B8 (enExample)
CA (2) CA3033133C (enExample)
ES (1) ES2534947T3 (enExample)
IL (2) IL215288A (enExample)
MX (1) MX2011010050A (enExample)
PL (1) PL2411521T3 (enExample)
PT (1) PT2411521E (enExample)
WO (1) WO2010111485A1 (enExample)
ZA (1) ZA201107774B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411521B1 (en) 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
EP3520814A1 (en) 2010-09-22 2019-08-07 Ena Therapeutics Pty Ltd Immunostimulating composition
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CA2950293A1 (en) * 2014-06-02 2015-12-10 Baylor Research Institute Methods and compositions for treating allergy and inflammatory diseases
WO2016044839A2 (en) * 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MX2019005502A (es) 2016-11-09 2020-10-01 Univ Texas Metodos y composiciones para inmunomodulacion adaptativa.
JP6750468B2 (ja) * 2016-11-18 2020-09-02 アイシン精機株式会社 内燃機関
UY37816A (es) 2017-07-20 2019-02-28 Spogen Biotech Inc Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
CN108739670A (zh) * 2018-09-04 2018-11-06 乡宁县关王庙乡新杰养羊专业合作社 一种防治羊肾炎的方法
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
WO2021141121A1 (en) * 2020-01-10 2021-07-15 Sbi Biotech Co., Ltd. Novel tlr9 agonists
US20210317454A1 (en) * 2020-04-10 2021-10-14 Idera Pharmaceuticals, Inc. Use of a tlr9 agonist in methods for treating covid-19
EP4138909A1 (en) * 2020-04-19 2023-03-01 Englmeier, Ludwig Prophylaxis and treatment of coronavirus infection
WO2021237291A1 (en) * 2020-05-26 2021-12-02 Axelia Oncology Pty Ltd Treatment of coronavirus
CN113234130A (zh) * 2021-05-24 2021-08-10 安徽医科大学第四附属医院 一种卡氏肺孢子菌重组蛋白及其制备方法与应用
US20240358822A1 (en) * 2021-08-31 2024-10-31 Ena Respiratory Pty Ltd Allergy treatment
WO2025015118A1 (en) * 2023-07-11 2025-01-16 Rutgers, The State University Of New Jersey Pharmaceutical compositions and methods for treating fungal infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7461M (enExample) 1968-06-19 1970-01-05
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US4406889A (en) 1980-02-15 1983-09-27 Ciba-Geigy Corporation Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GR78246B (enExample) 1981-01-23 1984-09-26 Ciba Geigy Ag
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
WO1994006498A1 (en) 1992-09-23 1994-03-31 Fisons Plc Inhalation device
UA27938C2 (uk) 1992-10-19 2000-10-16 Д'Юра Фармас'Ютікалз, Інк Пристрій для розпилення лікарського засобу у формі порошку для інгаляції
WO1994016970A1 (en) 1993-01-19 1994-08-04 Glaxo Group Limited Device
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP0622375A1 (de) 1993-02-20 1994-11-02 Hoechst Aktiengesellschaft Chrysospermine, Peptidwirkstoffe aus Apiocrea chrysosperma mit pharmakologischer Wirkung, ein Verfahren zu Herstellung und Verwendung derselben
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US6066447A (en) 1994-01-26 2000-05-23 Novartis Corporation Modified oligonucleotides
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
ES2167987T3 (es) 1996-01-03 2002-05-16 Glaxo Group Ltd Dispositivo inhalador.
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
DE19642014B4 (de) 1996-10-11 2005-08-04 Pactec Verpackungsmaschinen-Fabrik Theegarten Gmbh & Co. Kg Vorrichtung zum Verpacken kleinstückiger Artikel im Falteinschlag
CA2268957C (en) 1996-10-25 2008-04-29 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0981625A2 (en) 1997-05-06 2000-03-01 Human Genome Sciences, Inc. $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DK1003850T3 (da) 1997-06-06 2009-09-07 Univ California Inhibitorer af DNA-immunstimulatorisk sekvensaktivitet
US6517839B1 (en) 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
IL139646A0 (en) 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
GB9905538D0 (en) 1999-03-10 1999-05-05 Glaxo Group Ltd A device
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
AU780979B2 (en) 1999-09-25 2005-04-28 Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
EP1252307B1 (en) 2000-01-26 2008-01-02 Idera Pharmaceuticals, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2001055341A2 (en) 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
EP1267618A1 (en) 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
PT1278761E (pt) 2000-05-01 2005-08-31 Hybridon Inc Modulacao da estimulacao imunitaria mediada por oligonucleotidos de cpg, por modificacao posicional de nucleosidos
AU2001270134B2 (en) 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002022809A2 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US20050287612A1 (en) 2000-12-29 2005-12-29 John Bertin CARD-4 molecules and uses thereof
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
ES2421532T3 (es) 2001-06-21 2013-09-03 Dynavax Tech Corp Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
CN1642982A (zh) 2001-07-26 2005-07-20 唐诚公司 活化或抑制类Toll受体9的试剂
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
AU2002360278A1 (en) 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003067991A1 (en) 2002-02-13 2003-08-21 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
JP4846200B2 (ja) 2002-04-04 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 免疫賦活性ｇ、ｕ含有オリゴリボヌクレオチド
JP2006515266A (ja) 2002-04-22 2006-05-25 バイオニケ ライフ サイエンシーズ インコーポレイテッド オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1551376A4 (en) 2002-08-12 2010-10-06 Dynavax Tech Corp IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
NZ538719A (en) 2002-09-13 2008-05-30 Replicor Inc Non-sequence complementary antiviral oligonucleotides
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
US20040248837A1 (en) 2002-11-01 2004-12-09 Eyal Raz Methods of treating pulmonary fibrotic disorders
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
DK1569696T3 (da) 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
WO2004058759A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
UA84284C2 (ru) 2003-02-03 2008-10-10 Сирибас Байолоджикалз, Инк. Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
EP1608403A2 (en) 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004101600A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
AR044466A1 (es) 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
WO2005001055A2 (en) 2003-06-11 2005-01-06 Hybridon, Inc. Stabilized immunomodulatory oligonucleotides
EP1635846A4 (en) 2003-06-20 2009-01-28 Coley Pharm Gmbh SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
EP2363141A1 (en) 2003-07-15 2011-09-07 Idera Pharmaceuticals, Inc. Compsition comprising two oligonucleotides linked directly at their 3'ends wherein at leat one oligonucleotide has an accessible 5'end and the compound further comprising IL-2 used for synergistically stimulating an immune response in a patient.
US7491706B2 (en) 2003-07-25 2009-02-17 Changchun Huapu Biotechnology Co., Ltd. Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
US8673932B2 (en) 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
DE602004027940D1 (de) 2003-10-22 2010-08-12 Id Biomedical Corp Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
WO2005039504A2 (en) 2003-10-24 2005-05-06 Eisai Co., Ltd. Compounds and methods for treating toll-like receptor 2-related diseases and conditions
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
SG123799A1 (en) 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
WO2005060377A2 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
JP4772693B2 (ja) 2003-12-11 2011-09-14 ヴァックスデザイン・コーポレーション 免疫治療組成物、その製造方法及び使用方法
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20050239735A1 (en) 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
KR100558851B1 (ko) 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
WO2005097993A2 (en) 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
US20050222072A1 (en) 2004-02-20 2005-10-06 Hybridon, Inc. Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
EP1730281A2 (en) 2004-04-02 2006-12-13 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
EP1753453A2 (en) 2004-06-08 2007-02-21 Coley Pharmaceutical GmbH Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
MXPA06014915A (es) 2004-06-15 2007-08-20 Idera Pharmaceuticals Inc Multimeros oligonucleotidicos inmunoestimuladores.
US7427405B2 (en) 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
EP1781708B1 (en) 2004-07-09 2011-02-16 Variety Children's Hospital d/b/a/ Miami Children's Hospital Materials and methods for immune system stimulation
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2006060507A2 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
EP1835915A4 (en) 2004-12-30 2010-02-24 Coley Pharm Group Inc FORMULATIONS AND METHOD FOR MODIFYING THE IMMUNE RESPONSE
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530113A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法
US7560436B2 (en) * 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
CA2598992A1 (en) 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US8138173B2 (en) 2005-04-01 2012-03-20 3M Innovative Properties Company Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods
WO2006107851A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
HRP20070516A2 (en) 2005-04-08 2008-12-31 Coley Pharmaceutical Group Methods for treating infectious disease exacerbated asthma
US7405204B2 (en) 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006116458A2 (en) 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
ATE516817T1 (de) 2005-06-16 2011-08-15 Univ Gent Impfstoffe zur immunisierung gegen helicobacter
US20090220528A1 (en) 2005-06-17 2009-09-03 The Trustees Of The Univeristy Of Pennsylvania Cneter For Technology Transfer Stimulation of Toll-Like Receptors on T Cells
CA2614320A1 (en) 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CA2620582C (en) 2005-08-31 2015-11-10 Dennis M. Klinman Methods of altering an immune response induced by cpg oligodeoxynucleotides
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8076068B2 (en) 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
BRPI0616235A2 (pt) 2005-09-16 2011-06-14 Coley Pharm Gmbh acido ribonuclÉico monofilamentado imunoestimulante com cadeia principal de fosfodiÉster
EA013375B1 (ru) 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх МОДУЛЯЦИЯ ИММУНОСТИМУЛИРУЮЩИХ СВОЙСТВ КОРОТКОЙ ИНТЕРФЕРИРУЮЩЕЙ РИБОНУКЛЕИНОВОЙ КИСЛОТЫ (siРНК) С ПОМОЩЬЮ МОДИФИКАЦИИ НУКЛЕОТИДОВ
ES2542989T3 (es) 2005-10-12 2015-08-13 Idera Pharmaceuticals, Inc. Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
US8399423B2 (en) 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8426375B2 (en) 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2883957A1 (en) 2005-11-25 2015-06-17 Zoetis Belgium S.A. Immunostimmulatory oligoribonucleotides
AU2006336242A1 (en) 2005-12-20 2007-07-26 Idera Pharmaceuticals, Inc. Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
JP2009521218A (ja) 2005-12-20 2009-06-04 イデラ ファーマシューティカルズ インコーポレイテッド 異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド（ｉｍｏ（ｔｍ））の免疫賦活作用
DK2405002T3 (en) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonukleotidformuleringer
MX2008012993A (es) 2006-04-07 2008-12-18 Idera Pharmaceuticals Inc Compuestos de acido ribonucleico inmunomodulador estabilizado para receptores tipo toll-7 y receptores tipo toll-8.
WO2007118901A2 (en) 2006-04-18 2007-10-25 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Tracheal cytotoxin (tct) and related compounds for suppressing immune responses
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20080241139A1 (en) 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
US20090142362A1 (en) 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CA2668693A1 (en) * 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
JP2010512421A (ja) 2006-12-12 2010-04-22 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
US8188058B2 (en) 2007-04-19 2012-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
WO2009015107A1 (en) 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation of toll-like receptors for controlling neurogenesis
ES2585239T3 (es) 2007-08-01 2016-10-04 Idera Pharmaceuticals, Inc. Nuevos agonistas sintéticos de TLR9
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
CA2694973A1 (en) 2007-08-15 2009-02-19 Idera Pharmaceuticals, Inc. Toll like receptor modulators
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
US9872867B2 (en) 2008-06-06 2018-01-23 Tanya Kuritz Methods and compositions for modulation of innate immunity
EP2411521B1 (en) * 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
脂质体喷雾剂在给药系统研究中的应用;陈永刚等;《山西医药杂志》;20061130;第35卷(第11期);第983-985页 *

Also Published As

Publication number Publication date
US20120082700A1 (en) 2012-04-05
KR20170045371A (ko) 2017-04-26
CN102439153A (zh) 2012-05-02
CN105126072B (zh) 2020-05-15
JP6084655B2 (ja) 2017-02-22
PL2411521T3 (pl) 2015-08-31
CN103800906A (zh) 2014-05-21
WO2010111485A1 (en) 2010-09-30
US20150125492A1 (en) 2015-05-07
CA3033133A1 (en) 2010-09-30
AU2010229835A1 (en) 2011-10-13
JP2012522001A (ja) 2012-09-20
US20160074508A1 (en) 2016-03-17
PT2411521E (pt) 2015-04-21
ES2534947T3 (es) 2015-04-30
BRPI1009842B8 (pt) 2021-05-25
EP2411521B1 (en) 2015-01-14
MX2011010050A (es) 2011-12-14
CN103800906B (zh) 2017-09-22
KR101730351B1 (ko) 2017-04-28
US10722573B2 (en) 2020-07-28
CA3033133C (en) 2021-11-09
CN105126072A (zh) 2015-12-09
AU2010229835B2 (en) 2015-01-15
IL240202A0 (en) 2015-09-24
US9504742B2 (en) 2016-11-29
IL215288A (en) 2015-08-31
IL215288A0 (en) 2011-11-30
ZA201107774B (en) 2012-07-25
CA2756412C (en) 2019-02-26
BRPI1009842B1 (pt) 2021-01-05
US20250152703A1 (en) 2025-05-15
US9186400B2 (en) 2015-11-17
BRPI1009842A2 (pt) 2017-06-06
JP2015199747A (ja) 2015-11-12
HK1217176A1 (zh) 2016-12-30
KR20140014358A (ko) 2014-02-06
EP2411521A1 (en) 2012-02-01
US12201684B2 (en) 2025-01-21
US8883174B2 (en) 2014-11-11
US20170072052A1 (en) 2017-03-16
CA2756412A1 (en) 2010-09-30
US20200345842A1 (en) 2020-11-05
KR101856462B1 (ko) 2018-05-10
JP5759445B2 (ja) 2015-08-05

Similar Documents

Publication Publication Date Title
CN102439153B (zh) 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
Smaldone Repurposing of gamma interferon via inhalation delivery
CN118161614A (zh) 用tlr2激动剂治疗呼吸道感染
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
Gil et al. Inhalation delivery of interferon-λ-loaded pulmonary surfactant nanoparticles induces rapid antiviral immune responses in the lung
US11571455B2 (en) Methods and compositions for treating alcoholic liver disease
HK1217176B (zh) 用於刺激哺乳动物对病原体的先天免疫抵抗力的组合物
AU2015201861B2 (en) Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2021243148A2 (en) Methods and compositions for treating alcoholic liver disease
JP6649376B2 (ja) 肺の炎症を治療する方法
Evans et al. Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2017098474A1 (en) Antimicrobial peptide-loaded hyaluronic acid-based formulations, method of production and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant